( 90% is slowing down to perhaps its lo...)Big Pharma's continued hunger and search for new products

90%, is slowing down to perhaps its lowest growth in years. In fact, all of the other regions in the world outpaced the U.S. with rapid growth taking place in Latin America and Asia. Nevertheless, the sheer size of the U.S. market (and pricing and profits) drives M&A activity as companies look to establish a better regional foothold. As a result, M&A activity will continue pressured by:

<......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 05/22/06


Page: 1 2 3 4
Related biology technology :

1. Third Wave reports clinical growth, continued loss
2. Electronic Tele-Communications reports continued challenges
3. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
4. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
5. Control Your siRNA Research
6. Getting Started with MicroRNA Research
7. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
8. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
9. Research Organics
10. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
11. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)